<DOC>
	<DOCNO>NCT01597557</DOCNO>
	<brief_summary>The propose study design evaluate effect intravenous infusion magnesium sulfate facilitate successful cardioversion atrial fibrillation decrease energy threshold ( J ) require successful cardioversion atrial fibrillation sinus rhythm .</brief_summary>
	<brief_title>Intravenous Magnesium Infusion Patients Undergoing Cardioversion Atrial Fibrillation Trial</brief_title>
	<detailed_description>Patients atrial fibrillation may suffer disable symptom palpitation , shortness breath worsen heart failure . In patient , may beneficial convert rhythm sinus rhythm . Cardioversion achieve either pharmacologically electrically . Pharmacological cardioversion less successful acutely electrical cardioversion may associate complication prolongation QT interval torsades de pointes ( polymorphic ventricular tachycardia ) . Thus , cardioversion often accomplish electrically , use biphasic synchronized shock 75-200 Joules . Biphasic electrical cardioversion atrial fibrillation show successful ( i.e. , convert sinus rhythm ) 88 % time , average . The success rate appear largely depend upon duration arrhythmia presence severity structural heart disease . In study , evaluate effect intravenous magnesium sulfate success rate electrical cardioversion , also assess effect decrease energy level need successful cardioversion . If study successful , show simple inexpensive intervention increase success rate electrical cardioversion , increase proportion patient restore sinus rhythm . In addition , success lower energy level may improve safety cardioversion , high energy level likely associate side effect</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Magnesium Sulfate</mesh_term>
	<criteria>Patient new onset Atrial fibrillation le 48 hour onset undergoing electrical cardioversion . Patients atrial fibrillation longer 48 hour warfarin document therapeutic INR level &gt; 2 least 3 week prior cardioversion , dabigatran 3 week , transesophageal echocardiogram day procedure exclude intracardiac thrombus , undergoing electrical cardioversion . Creatinine &gt; 2.0 mg/dl Potassium level le 3.5 mmol/dl TSH &lt; 0.5 Magnesium level &gt; 3.0 mg/dl Urgent need cardioversion ( e.g. , hemodynamic instability , unstable angina , pulmonary edema ) Patients recent ( less 6 week ) acute myocardial infarction Patients postcardiac surgery Pregnant woman Patients treated antiarrhythmic drug receive less five dos drug . For amiodarone , patient receive less three week prior cardioversion exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Electrical Cardioversion</keyword>
	<keyword>Magnesium Sulfate</keyword>
</DOC>